secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001104659-22-061412
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics enters stock contribution for Baergic Bio; Nasdaq non-compliance for audit committee
--------------------------------------------------------------------------------

- Entered stock contribution agreement with parent Fortress to acquire 100% of Baergic Bio; conditions include $7.5M equity financing and repurchase of InvaGen shares.
- Director Jay Kranzler determined not independent under Nasdaq rules; resigned from audit committee on May 13, 2022.
- Company notified Nasdaq of non-compliance with audit committee composition rule; cure period available under Nasdaq Rule 5605(c)(4).
- Faith L. Charles appointed to Board and audit committee to fill vacancies, effective May 16, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922061412/0001104659-22-061412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922061412/tm2215290d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-061412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer